Neurology:追踪卒中后记忆轨迹变化,记忆减退难以避免,血管内治疗或免于卒中后更严重记忆缺失

2022-01-16 Naomi MedSci原创

近日,有研究人员调查了18个欧洲国家首次卒中和复发卒中前后的记忆轨迹, 发现首次卒中和反复卒中后记忆力急剧下降,但并非加速下降。改进的血管内治疗可能与卒中后较少的记忆丧失有关,还需更多基于个体水平证据

      世界各地的队列研究表明,随着时间的推移,卒中后会出现认知衰退,影响言语记忆、言语流利性、时间定向、处理速度、执行功能和整体认知。然而,这种联系的确切时间尚不清楚。几项队列研究已经估计了首次卒中前后的认知转变,但结果好坏参半,这可能是由于认知测量的差异。美国的一项研究(2010-2012年)发现,首次卒中后认知下降的速度几乎是之前的2倍。英国的一项研究(2002-2015年)表明,首次卒中后整体认知、言语记忆、言语流畅性和时间定向都急剧且加速下降。而另一项美国研究(1998-2008年)表明,首次卒中后记忆力急剧下降,但下降速度与卒中前相似。2003年-2013年美国的一项研究报告称,首次卒中后全球认知和言语记忆急剧下降,但下降速度与卒中前相似。

     研究还发现,与未复发的患者相比,卒中复发患者在多个认知领域的下降幅度更大。然而,这些研究的随访年限有限(≤为3年),重复的认知测量相对较少(≤3次)。

      欧洲健康、老龄化和退休调查(SHARE)的数据提供了在多个国家调查卒中事件与认知之间关系的机会。有证据表明欧洲各国在获得和提供急性卒中护理方面存在不均衡。近日,有研究人员调查了18个欧洲国家首次卒中和复发卒中前后的记忆轨迹,并测试了国家级急性卒中护理是否与卒中后记忆变化有关。

      数据来自欧洲健康、老龄化和退休调查(2004-2019年)。首次卒中和复发性卒中在基线无卒中的个体中被识别。在每个国家内,每个发生卒中的参与者(病例组)与一个没有卒中的个体(对照组)使用倾向得分匹配进行匹配。采用多水平分段线性回归方法对两组患者首次卒中和反复卒中前后的急性和加速记忆变化(以即刻和延迟单词回忆测试总分衡量,0-20个单词)进行量化。比较不同急性卒中护理指标水平的国家之间卒中和记忆之间的关系。

  • 最终的分析样本包括35,164名基线(≥为50岁)无卒中的参与者。在2004年-2019年期间,共发现2362例首次卒中和341例复发卒中;
  • 在病例组,首次卒中和复发卒中后记忆分数的平均急性下降分别为0.48(95%可信区间:0.31,0.65)和1.14(95%可信区间:0.80,1.48),与一系列混杂因素无关;
  • 在假想的非卒中发病日期之后,对照组没有观察到这样的急剧下降;
  • 在两组中,记忆力随着时间的推移而下降,但衰减率相似(-0.07[95%可信区间:-0.10,-0.05]对-0.06[95%可信区间:-0.08,-0.05]单词/年);
  • 在更容易获得血管内治疗的国家中,首次卒中和复发卒中后记忆力评分的平均急性下降幅度较小。

      研究发现首次卒中和反复卒中后记忆力急剧下降,但并非加速下降。改进的血管内治疗可能与卒中后较少的记忆丧失有关,但还需要更多基于个体水平数据的证据。应在老龄人口中对卒中进行早期评估和深入预防,促进卒中患者获得和提供急性卒中护理。

文献来源:Lu W, Richards M, Werring D, Bobak M. Memory Trajectories Before and After First and Recurrent Strokes [published online ahead of print, 2021 Dec 10]. Neurology. 2021;10.1212/WNL.0000000000013171. doi:10.1212/WNL.0000000000013171

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671458, encodeId=d8bb16e1458c3, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Dec 11 14:05:40 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204332, encodeId=147a120433202, content=吡拉西坦有用吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c86477226, createdName=ms5000002138253687, createdTime=Sun Mar 20 13:04:00 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001690, encodeId=ba67200169033, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 18 02:05:40 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188740, encodeId=b3bc1188e40ee, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Fri Jan 28 07:21:43 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185413, encodeId=5f821185413c4, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Tue Jan 18 00:49:29 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671458, encodeId=d8bb16e1458c3, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Dec 11 14:05:40 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204332, encodeId=147a120433202, content=吡拉西坦有用吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c86477226, createdName=ms5000002138253687, createdTime=Sun Mar 20 13:04:00 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001690, encodeId=ba67200169033, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 18 02:05:40 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188740, encodeId=b3bc1188e40ee, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Fri Jan 28 07:21:43 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185413, encodeId=5f821185413c4, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Tue Jan 18 00:49:29 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-03-20 ms5000002138253687

    吡拉西坦有用吗

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1671458, encodeId=d8bb16e1458c3, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Dec 11 14:05:40 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204332, encodeId=147a120433202, content=吡拉西坦有用吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c86477226, createdName=ms5000002138253687, createdTime=Sun Mar 20 13:04:00 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001690, encodeId=ba67200169033, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 18 02:05:40 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188740, encodeId=b3bc1188e40ee, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Fri Jan 28 07:21:43 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185413, encodeId=5f821185413c4, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Tue Jan 18 00:49:29 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-11-18 yinhl1978
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671458, encodeId=d8bb16e1458c3, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Dec 11 14:05:40 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204332, encodeId=147a120433202, content=吡拉西坦有用吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c86477226, createdName=ms5000002138253687, createdTime=Sun Mar 20 13:04:00 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001690, encodeId=ba67200169033, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 18 02:05:40 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188740, encodeId=b3bc1188e40ee, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Fri Jan 28 07:21:43 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185413, encodeId=5f821185413c4, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Tue Jan 18 00:49:29 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-28 moyanju2796

    学习了。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1671458, encodeId=d8bb16e1458c3, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Dec 11 14:05:40 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204332, encodeId=147a120433202, content=吡拉西坦有用吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c86477226, createdName=ms5000002138253687, createdTime=Sun Mar 20 13:04:00 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001690, encodeId=ba67200169033, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 18 02:05:40 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188740, encodeId=b3bc1188e40ee, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Fri Jan 28 07:21:43 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185413, encodeId=5f821185413c4, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Tue Jan 18 00:49:29 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-18 ms5000000254917531

    涨知识了

    0

相关资讯

免费回放:脑卒中患者用药方案及解惑

空军军医大学第一附属医院 (西京医院)史明博士

Stroke:随访20年,儿童中风后,长期死亡率如何

小儿缺血性脑卒中后的长期死亡率增加

European Radiology:对于脑卒中患者来说,仅仅使用CT还远远不够!

缺血性卒中是导致患者严重残疾的主要原因之一,也是全世界心血管疾病死亡的主要原因。

Stroke:脑卒中,晚期时间窗血管内治疗,男女或无差异

在对接受血管内治疗的晚期患者的多中心分析中,性别与功能结局没有关系

JAMA子刊:门诊or住院?TIA患者就诊选择对日后卒中发生有大影响!

短暂性脑缺血发作(TIA)往往表明随后发生脑缺血事件的高风险。

Stroke:妊娠高血压疾病,对脑卒中风险的影响如何?

HDP对未来卒中风险的影响持续了17年,无论是缺血性卒中还是出血性卒中

拓展阅读

卒中计划早期诊断评分表(ASPECTS评分)

卒中计划早期诊断评分表(ASPECTS评分)

SVN:系统性红斑狼疮患者中风风险的十年跟踪调查

系统性红斑狼疮患者发生持续10年的缺血性中风的风险仍增高,同时由于出血性中风的风险,系统性红斑狼疮患者应谨慎使用抗血小板药物,以预防心血管事件的发生。

European Radiology:聚焦CT血管造影选择性显示卒中相关动脉的技术可行性

现阶段,深度学习彻底改变了图像后处理,并可用于许多医学图像执行任务。

神经科一周速递:热点解读进展大盘点!

一周热点分享 ,紧跟神经科学前沿,让每一次诊疗都更精准,点击立即查看!

Stroke:卒中与癫痫风险—— 一项基于丹麦全国登记的研究

脑卒中后癫痫的绝对和相对风险估计值均低于之前的研究。

【今日分享】脑卒中一级预防的最佳证据总结

本指南:总结了脑卒中危险因素的一级预防内容,为临床护理人员提供全面、详细、规范的健康管理依据。点击即可下载查看。

2023 AHA/ASA科学声明:缺血性和出血性卒中后认知障碍

美国心脏协会(AHA,American Heart Association) · 2023-05-01

2021 ESO/EAN联合指南:卒中后认知障碍

欧洲卒中组织(ESO,European Stroke Organisation) · 2021-09-03

中国卒中后认知障碍防治研究专家共识

中国卒中学会 · 2020-02-28